How To See An Asteroid Bigger Than A Football Stadium Come Close On Thursday
An asteroid the size of a football stadium will fly safely by Earth on Friday, May 9, 2025, 23 years after its discovery. For such a large object to come close to Earth is rated as a once-per-year event, but it won't pose any threat. The Virtual Telescope Project will show it live at 20:30 UTC (3:30 p.m. EDT) on Thursday, May 8, 2025.
Asteroid (612356) 2002 JX8 will come within 2.6 million miles (4.2 million kilometers) of the planet — about 10.9 times farther than the moon, according to the Center for Near-Earth Object Studies at NASA's Jet Propulsion Laboratory. The moon is, on average, 238,855 miles/384,400 kilometers from Earth.
That may not sound close — and it certainly poses no danger to Earth — but for an asteroid, this large to come this close is a relatively rare event.
Any object that comes within 4.6 million miles of Earth and is larger than 492 feet is capable of causing significant regional damage in the event of impact. Asteroid (612356) 2002 JX8 is 950 feet (290 meters) wide and therefore referred to as a 'potentially hazardous object' by NASA.
Asteroid (612356) 2002 JX8 is classed as an Aten asteroid, which means it orbits the sun in less than a year and is often hidden in its glare as seen from Earth but crosses Earth's orbit. The Next Asteroid Close Approach
On June 5, 2025, asteroid 424482 (2008 DG5) will come within 2.2 million miles (3.5 million kilometers) of Earth — about 8.4 times farther than the moon. At up to 2,300 feet (700 meters), it's about the size of the Golden Gate Bridge; its close pass is rarer than the 2002 JX8. 2008 DG5 is an Apollo asteroid, which means its orbital pass crosses Earth's.
CNEO computes and characterizes the orbits of all known near-Earth objects — asteroids and comets — and predicts their close approaches with Earth. It's a critical part of NASA's Planetary Defense Program. Details of the next five close approaches are published on NASA's Asteroid Watch page. Asteroid YR4
Another near-Earth object, asteroid 2024 YR4, hit the headlines earlier this year when astronomers calculated that it would strike Earth on Dec. 22, 2032. Discovered on Dec. 27, 2024, by the Asteroid Terrestrial-impact Last Alert System in Chile, 2024 YR4 measures about 130 to 300 feet (40 to 90 meters) in diameter.
NASA's Center for Near-Earth Object Studies updated the asteroid's impact probability to 3.1%, the highest ever recorded for an object of this size, but after hundreds of observations on Feb. 24, it reduced this probability to almost zero.
Wishing you clear skies and wide eyes.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox News
42 minutes ago
- Fox News
Buzz Aldrin commemorates Apollo 11 moon landing milestone on 56th anniversary with heartfelt message
Legendary astronaut Edwin Eugene "Buzz" Aldrin Jr. shared a heartfelt message on the 56th anniversary of the Apollo 11 mission, recalling the historic moment when the lunar module Eagle landed at Tranquility Base. The 95-year-old, who in 1969 walked on the Moon behind mission commander Neil Armstrong, reminisced about the iconic moment they shared while Michael Collins orbited above in the command module. "July 20, 1969. "Contact light, engine stop." The Apollo 11 lunar module Eagle touched down at Tranquility Base on the Moon. A few hours later, Neil Armstrong and I stepped foot on the Moon, with Michael Collins orbiting close-by," Aldrin wrote in a post on X. Aldrin emphasized that this monumental achievement stemmed from years of relentless effort, unwavering dedication, and the teamwork of hundreds of thousands. "An achievement resulting from years of incalculable effort, commitment, and team work." Aldrin invoked President John F. Kennedy's powerful challenge to reach the Moon and see Kennedy's "words become reality." "We choose to go to the Moon in this decade and do the other things, not because they are easy, but because they are hard; because that goal will serve to organize and measure the best of our energies and skills, because that challenge is one that we are willing to accept, one we are unwilling to postpone, and one we intend to win, and the others too," Aldrin wrote, sharing Kennedy's speech he had given at Rice University in September 1962. The speech, delivered to inspire national unity and ambition, set the stage for achieving the decade's most audacious goal. "Well, space is there, and we're going to climb it, and the Moon and the planets are there, and new hopes for knowledge and peace are there. And, therefore, as we set sail we ask God's blessing on the most hazardous and dangerous and greatest adventure on which man has ever embarked," Kennedy's speech concluded, according to the JFK Library. Aldrin closed with a message of pride and gratitude, honoring all who made the mission possible and extending his blessings to the United States and all of humanity. "I couldn't be prouder to have completed this mission with the hundreds of thousands of people that helped get us to the moon and back home. God bless the USA and all of humankind," Aldrin wrote. Aldrin also shared that Pope Leo XIV spoke with him and his wife, expressing how special the moment was. "Anca and I were grateful and touched to receive the highest blessing today, from His Holiness, Pope Leo XIV on the 56th Anniversary of the Apollo 11 moon landing," Aldrin wrote. "What an honor! We prayed for good health, long life, and prosperity for all humankind." The Apollo 11 mission was the first in human history to land men on earth's satellite, fulfilling a dream as old as humanity itself. Armstrong was the first astronaut to step on the lunar surface at 9:56 p.m. ET on July 20, 1969. He was followed 19 minutes later by Aldrin. Aldrin is the only one of the three astronauts on the Apollo 11 mission still alive today. Stepheny Price is a writer for Fox News Digital and Fox Business. She covers topics including missing persons, homicides, national crime cases, illegal immigration, and more. Story tips and ideas can be sent to
Yahoo
an hour ago
- Yahoo
Cloudbreak Pharma Inc. Announces Positive Phase 2 Results for CBT-004 in Patients with Vascularized Pinguecula
Novel preservative-free CBT-004 eye drop formulation demonstrates statistically significant improvements in conjunctival hyperemia and patient-reported symptoms with excellent safety profile IRVINE, Calif., July 21, 2025--(BUSINESS WIRE)--Cloudbreak Pharma Inc. a clinical-stage ophthalmology company developing innovative therapies for ocular surface diseases, today announced positive topline results from its Phase 2 clinical trial evaluating CBT-004 ophthalmic solution in patients with vascularized pinguecula and associated conjunctival hyperemia. Key Phase 2 Results Primary Endpoint Achieved: Both investigated concentrations of CBT-004 demonstrated statistically significant improvements in conjunctival hyperemia compared to vehicle at Day 28, as assessed by an independent reading center using digital imaging. Rapid Onset and Sustained Efficacy: Significant improvements were observed as early as Day 7 with the highest investigated concentration CBT-004 , with benefits persisting through the 28-day treatment period. Significant Symptom Relief: Both CBT-004 concentrations showed statistically significant improvements in five common patient-reported symptoms including burning/stinging, itching, foreign body sensation, eye discomfort, and pain compared to vehicle. Excellent Safety Profile: No treatment-related adverse events were observed. Most adverse events were mild to moderate. No clinically meaningful changes in visual acuity or intraocular pressure were reported. Addressing a Significant Unmet Medical Need Vascularized pinguecula affects millions of Americans and represents a substantial unmet medical need in ophthalmology. This common, benign conjunctival growth can become problematic when it develops abnormal blood vessels and inflammation, which can lead to persistent redness, irritation, pain, and foreign body sensation. Current management options are limited, with many patients relying on off-label corticosteroids or surgical excision, both of which carry significant limitations and potential complications. Study Design and Results The multicenter, randomized, double-masked, vehicle-controlled Phase 2 study enrolled 88 adult patients with vascularized pinguecula and associated conjunctival hyperemia. Participants were randomized to receive one of two concentrations of CBT-004, or vehicle. The primary endpoint was the change from baseline in conjunctival hyperemia at Day 28, as measured by an independent reading center using standardized digital imaging protocols. Expert Commentary "There is a significant unmet need for patients suffering from symptomatic pinguecula, as current therapies are largely off-label and may carry safety concerns with long-term use," said Dr. John Hovanesian, Clinical Professor of Ophthalmology and recognized key opinion leader in anterior segment disease. "The results from this trial are exciting, as they demonstrate that a targeted, non- steroidal therapy can meaningfully improve both the clinical signs and symptoms that impact patients' quality of life." "As a principal investigator in this study, I was impressed by the consistency and magnitude of improvement in both objective redness and patient-reported discomfort with CBT-004," commented Dr. Sherif El-Harazi, Medical Director at Global Research Management. "The safety profile was excellent, and I believe this therapy could represent a meaningful advance for our patients with vascularized pinguecula." About CBT-004 CBT-004 is a novel, preservative-free topical ophthalmic solution containing a potent and selective inhibitor of vascular endothelial growth factor (VEGF) receptors and platelet-derived growth factor (PDGF) receptors. The formulation is specifically designed to reduce abnormal blood vessel growth and inflammation associated with vascularized pinguecula while minimizing potential ocular surface toxicity through its preservative- free composition. Next Steps and Regulatory Strategy Based on these positive Phase 2 results, Cloudbreak Pharma Inc. plans to advance CBT-004 into Phase 3 development and initiate discussions with the U.S. Food and Drug Administration (FDA) to establish the regulatory pathway toward potential approval. The company anticipates providing updates on Phase 3 study design and timing in the coming months. Market Opportunity The vascularized pinguecula market represents a significant commercial opportunity with limited therapeutic options. The prevalence of pinguecula increases with age and UV exposure, affecting a substantial portion of the aging population. With no FDA-approved treatments specifically indicated for this condition, CBT-004 has the potential to become a category-defining therapy in this underserved market. About Cloudbreak Pharma Inc. Cloudbreak Pharma Inc. is a clinical-stage ophthalmology company dedicated to developing innovative therapies for ocular surface diseases with high unmet medical need. The company's pipeline focuses on novel treatments targeting inflammation, vascularization, and other pathological processes affecting the ocular surface. Cloudbreak is committed to improving outcomes for patients with challenging eye conditions through scientifically-driven therapeutic development. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the potential therapeutic benefits of CBT-004, the company's clinical development plans, regulatory strategy, and market opportunity. These forward-looking statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause actual results to differ include, but are not limited to, the uncertainty of clinical trial results, regulatory approval processes, competitive developments, and other risks detailed in the company's filings. The company undertakes no obligation to update these forward-looking statements except as required by law. Please note that the information contained in this press release may not be complete. For further details about Cloudbreak Pharma Inc., and our drug candidates, please refer to our company's website (at View source version on Contacts Contact Information: Cloudbreak Pharma media@ Web: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Boston Globe
2 hours ago
- Boston Globe
Pope Leo XIV marks 56th anniversary of moon landing with observatory visit, call to Buzz Aldrin
This was Pope Leo's first visit to the observatory, founded in 1891 by Leo XIII. The first vision of it, however, can be traced back to the establishment by Pope Gregory XIII of a commission aimed at studying the scientific data and implications of the calendar reform that took place in 1582. Advertisement The Vatican Observatory has generated top-notch research from its scientist-clerics, drawing academics to its meteorite collection, which includes bits of Mars and is considered among the world's best. Later Sunday, the pope called astronaut Buzz Aldrin, who shared with Neil Armstrong and Michael Collins the historic 1969 moonwalk. 'This evening, 56 years after the Apollo 11 moon landing, I spoke with the astronaut Buzz Aldrin,' Pope Leo, the first U.S. born Pope, wrote on his X account. 'Together we shared the memory of a historic feat, a testimony to human ingenuity, and we reflected on the mystery and greatness of Creation.' Pope Leo then blessed the astronaut, his family and his collaborators. Aldrin, 95, is the last living astronaut of the historic Apollo 11 mission. He earned a doctorate in astronautics from the Massachusetts Institute of Technology. Advertisement There are a few precedents of papal calls to 'space.' In 2011, Pope Benedict XVI rang the space station and asked about the future of the planet and the environmental risks it faced. Before Benedict, Pope Paul VI sent a radio message to astronauts Armstrong, Aldrin and Collins after their moonwalk, calling them 'conquerors of the Moon.' Although Armstrong was the first to set foot on the moon, Aldrin followed him down the ladder of the Eagle Lander. 'He gazed at the lunar landscape and spontaneously remarked to Houston, 'Beautiful, beautiful. Magnificent desolation,' according to Aldrin's official website. FILE - The reflections of astronaut Neil Armstrong, the U.S. flag, the lunar module and a television camera are seen in the face mask of astronaut Edwin "Buzz" Aldrin when his picture was made by Armstrong as they walked across the surface of the moon, July 20, 1969. (Neil Armstrong/NASA via AP, File) Neil Armstrong/Associated Press
